CURRICULUM VITAE Dr. Vijay Kumar Prajapati, PhD, · PDF fileDepartment of Biochemistry, Central University of Rajasthan, Kishangarh, India CURRICULUM VITAE Dr. Vijay Kumar Prajapati,

Department of Biochemistry, Central University of Rajasthan, Kishangarh, India

CURRICULUM VITAE

Dr. Vijay Kumar Prajapati, PhD, MNAScAssistant ProfessorDepartment of BiochemistryCentral University of RajasthanNH-8 Bandarsindri, KishangarhAjmer, 305 817, Rajasthan, IndiaE-mail: [email protected], [email protected]: +91 7597271362Website- http://vkprajapati-lab.webs.com/

Academics/Profile1. Assistant Professor (Aug 2013 – till present)- Department of Biochemistry, School of Life

sciences, Central University of Rajasthan, Kishangarh, Ajmer, India.2. Assistant Professor (June - Jul 2013)- Department of Biochemistry, HNB Garhwal University,

Srinagar, Garhwal, Uttarakhand, India3. Postdoctoral Fellow (Nov 2012- June 2013) - Mitchell Cancer Institute, University of South

Alabama, Mobile, Alabama, United States of America.4. Scientist (Dec 2011- Oct 2012)- Department of Medicine, Institute of Medical Sciences, Banaras

Hindu University, Varanasi, India5. Doctor of Philosophy (PhD) in Biochemistry (2007-2011)- Department of Medicine, Institute of

Medical Sciences, Banaras Hindu University, Varanasi, India6. M.Sc. in Biochemistry (2004-2006)- Faculty of Sciences, Banaras Hindu University, Varanasi,

India7. B.Sc. (Hons.) in Chemistry (2001-2004)- Faculty of Sciences, Banaras Hindu University,

Varanasi, India

Awards International travel award from Strategic Network on Neglected Diseases and Zoonoses,

Belgium to attend Trieste Course Leishmania 2014 at Italy, Oct 2014. International travel award from DBT, India to attend Advanced Workshop on Interdisciplinary

Views on Chromosome Structure and Function at ICTP, Trieste, Italy, Sept 2014. Elected as MNASc, (Member, The National Academy of Sciences, India) May 2014. Best Oral Presentation Award in Global Infectious Diseases training program 2013 at ICGEB,

Cape Town, South Africa. ICGEB fellowship to attend Global Infectious Diseases Research training program at Cape

Town, South Africa. International travel award from Strategic Network on Neglected Diseases and Zoonoses,

Belgium to attend 5th World Congress on Leishmaniasis at Brazil, May 2013. Ranbaxy Science Scholar Award-2011 for young scientist from Ranbaxy Science Foundation,

Gurgaon, India. (http://www.ranbaxysciencefoundation.org/RanSciScholarsmain.asp)


CURRICULUM VITAE









Varanasi, India









CURRICULUM VITAE









Varanasi, India









WHO fellowship to attend “Advanced WHO-IRTC/UNIL Course on Immunology, Vaccinologyand Biotechnology applied to Leishmania” at University of Lausanne, Switzerland, organizedby Prof Fabienne Tacchini-Cottier in October 2011.

ICMR, India & ESF travel award to attend 3rd European Science Foundation Summer SchoolNanomedicine 2011 at Lutherstadt Wittenberg, Germany, June 2011.

DST, India & ICGEB travel award to attend a course work at ICGEB, Italy on the “MouseGenetics; Models for Human Diseases” February 2011.

Certificate of Merit from Nanoscience and Technology Unit, BHU for R&D effort onNanomedicine drug delivery on the occasion of India Independence day, August 2010.

European Commission fellowship for 6 week internship with Prof. Jean-Claude Dujardinin the Institute of Tropical Medicine, Antwerp, Belgium, and Prof. Louis Maes at Universityof Antwerp, Belgium, April-May 2009.

Awarded Research Projects-

1. UGC (2014-15) as Principal Investigator- Antileishmanial activity of silver nanoparticlesattached to amphotericin B. (Amount- 06 Lakhs)

Administrative Responsibilities at Central University of Rajasthan-

1. Member Secretary- Institutional Animal Ethical Committee, Central University of Rajasthan.2. Member- Institutional Human Ethical Committee, Central University of Rajasthan.3. Member- NCC/NSS Committee, Central University of Rajasthan.4. President for Tennis game, Central University of Rajasthan (2013-14).5. Member- Scientific instrument purchase committee, Dept of Biochemistry, CURAJ.6. Member- Admission Committee for UG, PG & PhD, Dept of Biochemistry, CURAJ.7. Contact Person from CURAJ for www.snndz.net Belgium based funding agency.

National Level Examinations National Eligibility Test (NET) for Lectureship, conducted by UGC & CSIR India Junior Research Fellowship of Indian Council of Medical Research, India Graduate Aptitude Test in Engineering and Technology (GATE) 59th Rank in India

conducted by Indian Institute of Technology (IIT), Kharagpur, India.Honorary Scientific Work

PhD Thesis Examiner- Banaras Hindu University, India. Editor- Journal of Molecular Biomarkers & Diagnosis (IF-1.98) Advisor- The Journal of Infection in Developing Countries (IF-1.2) Editor- Journal of Infectious Diseases and Therapy Volunteer Reviewer- PLoS ONE, Drug Design Development and Therapy; International Journal

of Nanomedicine; Bioorganic & Medicinal Chemistry Letters, Infection and Drug Resistance;OncoTargets and Therapy; International Journal of Nanoparticles, Frontiers in Non-CodingRNA.


Research Guidance- Presently, I am guiding two Ph.D. students for research work and six M.Sc.students yearly for dissertation work.

Publications (Total publications-22, Cumulative impact factor ~85, Citations ~375, h-index-11)

1. Perry MR, Prajapati VK, Menten J, Raab A, Feldmann J, Chakraborti D, Sundar S, Fairlamb AH,Boelaert M, Picado A. Arsenic Exposure and Outcomes of Antimonial Treatment in VisceralLeishmaniasis Patients in Bihar, India: A Retrospective Cohort Study. PLoS Neglected TropicalDiseases. 2;9(3), 2015, e0003518. (IF- 4.69)

2. Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanershchot M, Dujardin JC, Sundar S; Invitro susceptibility of Leishmania donovani to Miltefosine in Indian Visceral Leishmaniasis.American Journal of Tropical Medicine & Hygiene, 89 (4), 2013, 750-754. (IF-2.59)

3. Prajapati VK* and Mehrotra S. Advances in the Diagnosis of Visceral Leishmaniasis. Journal ofMolecular Biomarker and Diagnosis. 4 (2); 2013, 1000e118. (IF- 2.04)

4. Prajapati VK, Mehrotra S, Gautam S, Rai M and Sundar S; In Vitro Antileishmanial DrugSusceptibility of Clinical Isolates from Patients with Indian Visceral Leishmaniasis- Status of NewlyIntroduced Drugs. American Journal of Tropical Medicine & Hygiene. 87(4), 2012, 655–657.(IF-2.59)

5. Sundar S, Singh A, Rai M, Prajapati VK, Singh A, Ostyn B, Boeleart M, Dujardin JC, ChakravartyJ; Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis after a Decade of Use in India.Clinical Infectious Diseases. 2012 Aug; 55 (4): 543-50. (IF- 9.374) (Published as a News inNature doi:10.1038/nature.2013.12553)

6. Verma RK, Prajapati VK, Verma GK, Chakraborti D, Sundar S, Rai M, Dubey VK, Singh MS;Molecular docking and in vitro antileishmanial evaluation of chromene-2-thione analogues. ACSMedicinal Chemistry Letters. 3 (3), 2012, 243–247. (IF- 3.311)

7. Prajapati VK, Yadav TP, Awasthi K, Rai M, Srivastava ON and Sundar S; An Oral Formulation ofAmphotericin B Attached to Functionalized Carbon Nanotubes is an Effective Treatment forExperimental Visceral Leishmaniasis. Journal of Infectious Diseases, 205 (2), 2012: 333-6. (IF-5.848)

8. Srivastava P, Prajapati VK, Rai M, Sundar M. An unusual case of Amphotericin B refractoriness inVisceral Leishmaniasis from a non-endemic region of India. Journal of Clinical Microbiology; 49(8) : 2011; 3088-91. (IF- 4.153)

9. Prajapati VK, Awasthi K, Gautam S, Yadav TP, Rai M, Srivastava ON, Sundar S; Targeted killingof Leishmania donovani in vivo and in vitro with Amphotericin B attached to functionalized CarbonNanotubes; Journal of Antimicrobial Chemotherapy, 66 (4): 2011; 874-9. (IF- 5.338)(Published as research highlight by journal Nature; doi:10.1038/nindia.2011.74)

10. Srivastava P, Prajapati VK, Vanaerschot M, Auwera GVD, Dujardin JC, Sundar JC. Detection ofLeptomonas sp. parasites in clinical isolates of Kala-azar patients from India. Infection, Geneticsand Evolution, 10 (7): 2010; 1145-50. (IF- 2.768)

11. Maurya R, Mehrotra S, Prajapati VK, Nylén S, Sacks D, Sundar S. Evaluation of Blood agarmicro-titer plates for culturing Leishmania parasites to titrate the parasite burden in spleen andperipheral blood of VL patients. Journal of Clinical Microbiology. 48(5): 2010; 1932-4. (IF-4.153)


12. Maurya R, Kumar R, Prajapati VK, Manandhar KD, Sacks D, Sundar S, Nylén S. Human visceralleishmaniasis is not associated with expansion or accumulation Foxp3+ CD4 cells in blood orspleen. Parasite Immunology, 32, 2010, 479–483. (IF- 2.208)

13. Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S.Antileishmanial activity of nano-amphotericin B deoxycholate. Journal of AntimicrobialChemotherapy, 62(2), 2008:376-80. (IF- 5.338)

14. Manandhar KD, Yadav TP, Prajapati VK, Basukala O, Aganja RP, Dude A, Shrivastav ON,Sundar S. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivoapproach. Advances in Experimental Medicine and Biology. 808: 2014; 77-91. (IF- 2.012)

15. Hazra S, Ghosh S, Sarma MD S, Sharma S, Das M, Saudagar P, Prajapati VK, Dubey VK, SundarS, Hazra B; Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator ofornithine decarboxylase of Leishmania donovani. Experimental Parasitology. 135 (2013) 407-413.(IF- 2.154)

16. Bhardwaj A, Arora S, Prajapati VK, Singh S, Singh AP. Cancer Stemness- Regulating Micrornas:Role, Mechanisms and Therapeutic Potential; Current Drug Targets. 14 (10) : 2013; 1175-84. (IF-3.848)

17. Dayakar A, Chandrasekaran S, Prajapati VK, Veronica TSJR, Sundar S, Maurya R;A rapidmethod to assess the stage differentiation in Leishmania donovani by flow cytometry. ExperimentalParasitology. 132, (2012) 495–500. (IF- 2.154)

18. Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK,V. Ramesh, Sundar S, Schonian G,Dujardin JC, Salotra P; Drug Susceptibility in Leishmania Isolates following MiltefosineTreatment in cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis. PLoSNeglected Tropical Diseases. 6 (5), 2012;e1657. (IF- 4.69)

19. Sundar S and Prajapati VK; Drug targeting to infectious diseases by nanoparticles surfacefunctionalized with special biomolecules. Current Medicinal Chemistry; 19, 36, 2012; 3196-3202.(IF-4.07)

20. Hazra S, Ghosh S, Debnath S, Seville S, Prajapati VK, Wright CW, Sundar S, Hazra B.Antileishmanial activity of cryptolepine analogues, and apoptotic effects of 2, 7-dibromocryptolepine against Leishmania donovani promastigotes. Parasitology Research. 111,2012:195–203. (IF- 2.852)

21. Perry M, Wyllie S, Prajapati VK, Feldmann J, Sundar S, Boelaert M, Fairlamb AH. Visceralleishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in theIndian Subcontinent? PLoS Neglected Tropical Disease; 5 (9):201; e1227. (IF- 4.69)

22. Mukhopadhyay R, Mukherjee R, Mukherjee B, Naskar M, Mandal D, Decupere S, Ostyn B,Prajapati VK, Sundar S, Dujardin JC, Roy S. Characterisation of Leishmania donovani isolates:biochemical and biophysical studies and interaction with host cells. International Journal forParasitology, 41(13-14):2011; 1311-21. (IF- 3.637)


Publications under Communication23. Pandey RK, Sundar S and Prajapati VK*; MicroRNA Regulated T Helper Cell Differentiation and

Plasticity during Visceral Leishmaniasis Infection; In PLoS Neglected Tropical Diseases.24. Pandey RK, Prajapati P, Sharma T, Mandal CC and Prajapati VK*; Epidemiological Investigation

of a Jaundice outbreak in Kishangarh, Rajasthan, India, 2014; In EcoHealth.25. Pandey RK, Sundar S and Prajapati VK*; Imidazole analogues as potential inhibitor for

trypanothione reductase in Leishmania donovani: a molecular docking approach.

Conference/Workshop/Training

Invited to attend Sao Paulo School of Advanced Science on Neglected Diseases DrugDiscovery focus on Kinetoplastids (SPSAS-ND3); June 2015 in Brazil.

October 2014: ICGEB Leishmania course 2014 at Trieste, Italy. September 2014: Advanced Workshop on Chromosome Structure and Function, Trieste, Italy. February 2014; Young Investigator Meeting (YIM 2014) at Hyderabad, India. Dec 2013 to Jan 2014 (One Month)- Orientation course for teaching organized by JN Vyas

University, Jodhpur at Central University of Rajasthan, Ajmer, India. November 2013: ITM-Antwerp Colloquium on infectious diseases, Bangalore, India. October 2013: ICGEB course on Global Infectious Diseases, Cape Town, South Africa. May 2013; Worldleish5- Congress on Leishmaniasis; Brazil. October 2012; CDSA-NIH workshop at New Delhi, India. September 2012; Kaladrug-R workshop and meeting; Kathmandu, Nepal. October 2011; WHO-IRTC Immunology course work, Laussane, Switzerland. June 2011; Nanomedicine Summer School; Wittenberg, Germany. February 2011; ICGEB course work in Trieste, Italy. March 2009; Oral presentation at BHU, Varanasi, India. February 2009; Worldleish4- Congress on Leishmaniasis; Lucknow, India. September 2008; Bio-Rad’s Workshop on Bioplex-Multiplex, Gurgaon, India. December 2007; FACSCalibur Basic Training Course, Gurgaon, India.

Date- 27/05/2015 Signature- Vijay Kumar Prajapati

Documents

CURRICULUM VITAE Dr. Vijay Kumar Prajapati, PhD, · PDF fileDepartment of Biochemistry, Central University of Rajasthan, Kishangarh, India CURRICULUM VITAE Dr. Vijay Kumar Prajapati,